An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Melphalan (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Delcath Systems
- 30 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 Apr 2018.
- 30 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 30 Jan 2018 Status changed from recruiting to suspended due to limited enrollment